Akin, C., Sabato, V., Gotlib, J., Panse, J., Álvarez-Twose, I., Radia, D. H., . . . Castells, M. (2026). Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years. The journal of allergy and clinical immunology, 158(2), . https://doi.org/10.1016/j.jaci.2026.04.001
Cita Chicago Style (17a ed.)Akin, Cem, et al. "Avapritinib Achieves Long-term Disease Control with Favorable Safety in Patients with Indolent Systemic Mastocytosis over 3 Years." The Journal of Allergy and Clinical Immunology 158, no. 2 (2026). https://doi.org/10.1016/j.jaci.2026.04.001.
Cita MLA (9a ed.)Akin, Cem, et al. "Avapritinib Achieves Long-term Disease Control with Favorable Safety in Patients with Indolent Systemic Mastocytosis over 3 Years." The Journal of Allergy and Clinical Immunology, vol. 158, no. 2, 2026, https://doi.org/10.1016/j.jaci.2026.04.001.